Notification of Dilution of Voting Rights

RNS Number : 1450S
Hutchison China Meditech Limited
07 July 2020
 

Notification of Dilution of Voting Rights

 

 

London: Tuesday, July 7, 2020 : Hutchison China MediTech Limited ("Chi-Med") (Nasdaq/AIM: HCM) was notified that CK Hutchison Holdings Limited (" CK Hutchison ") shareholding1 in Chi-Med remains unchanged, at 332,478,770 ordinary shares of par value US$0.10 each in the capital of Chi-Med ("Shares"). 

 

Each American Depositary Share ("ADS") represents five Shares.  As announced on June 25, 2020, Chi-Med issued a total of 20,000,000 Shares (equivalent to 4,000,000 ADSs) to General Atlantic.  Chi-Med was notified on July 6, 2020 that this issuance diluted CK Hutchison's holding1 to 46.79 per cent of the total number of voting rights of Chi-Med.  The date on which the notification threshold was crossed was July 3, 2020.

 

 

About CK Hutchison

 

Listed on The Stock Exchange of Hong Kong Limited, CK Hutchison is a renowned multinational conglomerate committed to innovation and technology with businesses spanning the globe.  With operations in about 50 countries and over 300,000 employees worldwide, CK Hutchison has five core businesses - ports and related services, retail, infrastructure, energy and telecommunications. 

 

CK Hutchison reported turnover of approximately HK$440 billion (US$56 billion) for the year ended 31 December 2019.

 

For more information, please visit www.ckh.com.hk.

 

 

About Chi-Med

 

Chi-Med (Nasdaq/AIM: HCM) is an innovative biopharmaceutical company committed, over the past twenty years, to the discovery and global development of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.  It has a portfolio of eight cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China.  For more information, please visit: www.chi-med.com.

 

 

[1] Held through CK Hutchison's indirect wholly-owned subsidiary Hutchison Healthcare Holdings Limited.

 

CONTACTS

 

Investor Enquiries


Mark Lee, Senior Vice President

+852   2121   8200

Annie Cheng, Vice President

+1   (973)   567   3786



Media Enquiries

 

Americas - Brad Miles, Solebury Trout

+1   (917)   570   7340   (Mobile) 
bmiles@troutgroup.com

Europe - Ben Atwell / Alex Shaw, FTI Consulting

+44   20   3727   1030 / +44   7771   913   902   (Mobile) / +44 7779 545 055 (Mobile)
Chi-Med@fticonsulting.com

Asia - Joseph Chi Lo / Zhou Yi, Brunswick

+852   9850   5033 (Mobile), jlo@brunswickgroup.com / +852   97 83   6894  (Mobile), y zhou@brunswickgroup.com



Nominated Advisor


Freddy Crossley / Atholl Tweedie, Panmure Gordon (UK) Limited

+44   (20)   7886   2500

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TVRUNVRRRKUBRAR
UK 100